Healthcare [ 10/13 ] | Biotechnology [ 67/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 3, 23 | -0.14 Increased by +44% | -0.24 Increased by +41.67% |
| Aug 3, 23 | -0.15 Increased by +50% | -0.31 Increased by +51.61% |
| May 4, 23 | -0.27 Increased by +6.9% | -0.29 Increased by +6.9% |
| Mar 9, 23 | -0.22 Increased by +18.52% | -0.31 Increased by +29.03% |
| Nov 10, 22 | -0.25 Increased by +7.41% | -0.34 Increased by +26.47% |
| Aug 5, 22 | -0.3 Decreased by -7.14% | -0.31 Increased by +3.23% |
| May 5, 22 | -0.29 Decreased by -16% | -0.32 Increased by +9.38% |
| Mar 17, 22 | -0.27 Increased by +10% | -0.28 Increased by +3.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -8.19 M Increased by +42.84% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -8.99 M Increased by +49.64% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -14.92 M Increased by +12.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -12.11 M Increased by +23.15% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -14.32 M Increased by +9.33% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -17.85 M Decreased by -19.48% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -17.09 M Decreased by -51.4% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -15.75 M Decreased by -39.52% | Decreased by N/A% Decreased by N/A% |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.